Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement

Mostrar otras versiones (1)

We developed a severe acute respiratory syndrome (SARS) subunit recombinant protein vaccine candidate based on a high-yielding, yeast-engineered, receptor-binding domain (RBD219-N1) of the SARS beta-coronavirus (SARS-CoV) spike (S) protein. When formulated with Alhydrogel®, RBD219-N1 induced high le...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wen-Hsiang, Tao, Xinrong, Agrawal, Anurodh Shankar, Algaissi, Abdullah, Peng, Bi-Hung, Pollet, Jeroen, Strych, Ulrich, Bottazzi, Maria Elena, Hotez, Peter J., Lustigman, Sara, Du, Lanying, Jiang, Shibo, Tseng, Chien-Te K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508514/
https://www.ncbi.nlm.nih.gov/pubmed/33039209
http://dx.doi.org/10.1016/j.vaccine.2020.09.061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508514/
https://www.ncbi.nlm.nih.gov/pubmed/33039209
http://dx.doi.org/10.1016/j.vaccine.2020.09.061

Ejemplares similares